If it fails to get up, most likely on the basis of production concerns, then it's going to be very difficult for the subsequent products to also get up
Yes of course, if Remestemcel-L is overwhelmingly successful in the COVID-19 space I can see them just tossing it aside because Ryoncil was rejected .... NIH would have just poured $50m USD down the drain as well ... lol
MSB Trading 2020 - a new dawn, page-6257
-
- There are more pages in this discussion • 6,814 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |